Medical - Devices
Compare Stocks
5 / 10Stock Comparison
EDAP vs AEYE vs ALKT vs ISRG vs SYK
Revenue, margins, valuation, and 5-year total return — side by side.
Software - Application
Software - Application
Medical - Instruments & Supplies
Medical - Devices
EDAP vs AEYE vs ALKT vs ISRG vs SYK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Software - Application | Software - Application | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $156M | $100M | $1.87B | $161.07B | $112.69B |
| Revenue (TTM) | $70M | $40M | $472M | $10.58B | $25.12B |
| Net Income (TTM) | $-13M | $-3M | $-50M | $2.98B | $3.25B |
| Gross Margin | 46.8% | 78.3% | 57.4% | 66.3% | 63.5% |
| Operating Margin | -38.2% | -7.9% | -9.3% | 30.5% | 22.4% |
| Forward P/E | — | — | 21.7x | 43.8x | 19.6x |
| Total Debt | $28M | $721K | $354M | $303M | $14.86B |
| Cash & Equiv. | $17M | $5M | $63M | $3.37B | $4.01B |
EDAP vs AEYE vs ALKT vs ISRG vs SYK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 21 | May 26 | Return |
|---|---|---|---|
| Edap Tms S.a. (EDAP) | 100 | 60.5 | -39.5% |
| AudioEye, Inc. (AEYE) | 100 | 32.0 | -68.0% |
| Alkami Technology, … (ALKT) | 100 | 36.5 | -63.5% |
| Intuitive Surgical,… (ISRG) | 100 | 157.3 | +57.3% |
| Stryker Corporation (SYK) | 100 | 112.0 | +12.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EDAP vs AEYE vs ALKT vs ISRG vs SYK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
EDAP ranks third and is worth considering specifically for momentum.
- +80.9% vs ALKT's -37.8%
Among these 5 stocks, AEYE doesn't own a clear edge in any measured category.
ALKT is the clearest fit if your priority is growth exposure.
- Rev growth 32.9%, EPS growth -12.2%, 3Y rev CAGR 29.5%
- 32.9% revenue growth vs EDAP's 10.3%
ISRG is the #2 pick in this set and the best alternative if long-term compounding and sleep-well-at-night is your priority.
- 5.5% 10Y total return vs SYK's 187.1%
- Lower volatility, beta 1.02, Low D/E 1.7%, current ratio 4.87x
- 28.2% margin vs EDAP's -18.9%
- 14.8% ROA vs EDAP's -18.8%, ROIC 15.0% vs -69.2%
SYK carries the broadest edge in this set and is the clearest fit for income & stability and valuation efficiency.
- Dividend streak 34 yrs, beta 0.55, yield 1.1%
- PEG 1.32 vs ISRG's 2.01
- Beta 0.55, yield 1.1%, current ratio 1.89x
- Lower P/E (19.6x vs 43.8x), PEG 1.32 vs 2.01
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 32.9% revenue growth vs EDAP's 10.3% | |
| Value | Lower P/E (19.6x vs 43.8x), PEG 1.32 vs 2.01 | |
| Quality / Margins | 28.2% margin vs EDAP's -18.9% | |
| Stability / Safety | Beta 0.55 vs AEYE's 2.29 | |
| Dividends | 1.1% yield; 34-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +80.9% vs ALKT's -37.8% | |
| Efficiency (ROA) | 14.8% ROA vs EDAP's -18.8%, ROIC 15.0% vs -69.2% |
EDAP vs AEYE vs ALKT vs ISRG vs SYK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
EDAP vs AEYE vs ALKT vs ISRG vs SYK — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ISRG leads in 3 of 6 categories
SYK leads 2 • EDAP leads 0 • AEYE leads 0 • ALKT leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SYK is the larger business by revenue, generating $25.1B annually — 623.1x AEYE's $40M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to EDAP's -18.9%. On growth, EDAP holds the edge at +31.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $70M | $40M | $472M | $10.6B | $25.1B |
| EBITDAEarnings before interest/tax | -$24M | -$504,000 | -$12M | $3.8B | $6.3B |
| Net IncomeAfter-tax profit | -$13M | -$3M | -$50M | $3.0B | $3.2B |
| Free Cash FlowCash after capex | -$17M | $2M | $44M | $2.8B | $4.3B |
| Gross MarginGross profit ÷ Revenue | +46.8% | +78.3% | +57.4% | +66.3% | +63.5% |
| Operating MarginEBIT ÷ Revenue | -38.2% | -7.9% | -9.3% | +30.5% | +22.4% |
| Net MarginNet income ÷ Revenue | -18.9% | -7.6% | -10.6% | +28.2% | +12.9% |
| FCF MarginFCF ÷ Revenue | -25.1% | +5.5% | +9.4% | +26.8% | +17.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +31.4% | +7.9% | +28.9% | +23.0% | +11.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.3% | +29.0% | -22.7% | +18.8% | +56.0% |
Valuation Metrics
SYK leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 35.0x trailing earnings, SYK trades at a 39% valuation discount to ISRG's 57.6x P/E. Adjusting for growth (PEG ratio), SYK offers better value at 2.36x vs ISRG's 2.65x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $156M | $100M | $1.9B | $161.1B | $112.7B |
| Enterprise ValueMkt cap + debt − cash | $166M | $96M | $2.2B | $158.0B | $123.5B |
| Trailing P/EPrice ÷ TTM EPS | -5.33x | -32.36x | -37.89x | 57.62x | 35.03x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 21.69x | 43.84x | 19.62x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 2.65x | 2.36x |
| EV / EBITDAEnterprise value multiple | — | — | — | 43.62x | 20.31x |
| Price / SalesMarket cap ÷ Revenue | 2.20x | 2.49x | 4.20x | 16.00x | 4.49x |
| Price / BookPrice ÷ Book value/share | 8.02x | 20.91x | 5.00x | 9.17x | 5.02x |
| Price / FCFMarket cap ÷ FCF | — | — | 45.09x | 64.67x | 26.31x |
Profitability & Efficiency
ISRG leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-65 for EDAP. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to EDAP's 1.43x. On the Piotroski fundamental quality scale (0–9), ISRG scores 6/9 vs ALKT's 3/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -65.4% | -47.8% | -14.0% | +16.9% | +15.0% |
| ROA (TTM)Return on assets | -18.8% | -9.5% | -5.9% | +14.8% | +6.9% |
| ROICReturn on invested capital | -69.2% | -42.4% | -8.6% | +15.0% | +11.4% |
| ROCEReturn on capital employed | -56.0% | -17.7% | -9.3% | +16.5% | +13.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 | 3 | 6 | 6 |
| Debt / EquityFinancial leverage | 1.43x | 0.15x | 0.98x | 0.02x | 0.66x |
| Net DebtTotal debt minus cash | $10M | -$5M | $290M | -$3.1B | $10.8B |
| Cash & Equiv.Liquid assets | $17M | $5M | $63M | $3.4B | $4.0B |
| Total DebtShort + long-term debt | $28M | $721,000 | $354M | $303M | $14.9B |
| Interest CoverageEBIT ÷ Interest expense | -16.21x | -2.79x | -3.73x | — | 6.72x |
Total Returns (Dividends Reinvested)
ISRG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ISRG five years ago would be worth $15,873 today (with dividends reinvested), compared to $3,977 for AEYE. Over the past 12 months, EDAP leads with a +80.9% total return vs ALKT's -37.8%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.4% vs EDAP's -28.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +22.4% | -18.7% | -23.1% | -19.3% | -15.2% |
| 1-Year ReturnPast 12 months | +80.9% | -27.9% | -37.8% | -15.4% | -22.5% |
| 3-Year ReturnCumulative with dividends | -63.3% | +20.6% | +41.1% | +49.6% | +5.5% |
| 5-Year ReturnCumulative with dividends | -37.8% | -60.2% | -54.9% | +58.7% | +21.5% |
| 10-Year ReturnCumulative with dividends | +18.9% | +102.2% | -59.5% | +554.2% | +187.1% |
| CAGR (3Y)Annualised 3-year return | -28.4% | +6.4% | +12.2% | +14.4% | +1.8% |
Risk & Volatility
Evenly matched — EDAP and SYK each lead in 1 of 2 comparable metrics.
Risk & Volatility
SYK is the less volatile stock with a 0.55 beta — it tends to amplify market swings less than AEYE's 2.29 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EDAP currently trades 82.4% from its 52-week high vs AEYE's 49.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.77x | 2.29x | 1.30x | 1.02x | 0.55x |
| 52-Week HighHighest price in past year | $5.05 | $16.39 | $31.66 | $603.88 | $404.87 |
| 52-Week LowLowest price in past year | $1.21 | $5.31 | $14.11 | $427.84 | $289.91 |
| % of 52W HighCurrent price vs 52-week peak | +82.4% | +49.4% | +55.1% | +75.1% | +72.7% |
| RSI (14)Momentum oscillator 0–100 | 54.8 | 61.3 | 50.9 | 42.4 | 24.3 |
| Avg Volume (50D)Average daily shares traded | 38K | 194K | 1.9M | 1.8M | 2.1M |
Analyst Outlook
SYK leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: EDAP as "Buy", ALKT as "Buy", ISRG as "Buy", SYK as "Buy". Consensus price targets imply 44.2% upside for EDAP (target: $6) vs 26.2% for ALKT (target: $22). SYK is the only dividend payer here at 1.14% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $6.00 | — | $22.00 | $622.60 | $403.69 |
| # AnalystsCovering analysts | 8 | — | 12 | 55 | 50 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +1.1% |
| Dividend StreakConsecutive years of raises | — | 1 | 1 | — | 34 |
| Dividend / ShareAnnual DPS | — | — | — | — | $3.36 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +1.4% | 0.0% |
ISRG leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SYK leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.
EDAP vs AEYE vs ALKT vs ISRG vs SYK: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is EDAP or AEYE or ALKT or ISRG or SYK a better buy right now?
For growth investors, Alkami Technology, Inc.
(ALKT) is the stronger pick with 32. 9% revenue growth year-over-year, versus 10. 3% for Edap Tms S. a. (EDAP). Stryker Corporation (SYK) offers the better valuation at 35. 0x trailing P/E (19. 6x forward), making it the more compelling value choice. Analysts rate Edap Tms S. a. (EDAP) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — EDAP or AEYE or ALKT or ISRG or SYK?
On trailing P/E, Stryker Corporation (SYK) is the cheapest at 35.
0x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Stryker Corporation is actually cheaper at 19. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 32x versus Intuitive Surgical, Inc. 's 2. 01x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — EDAP or AEYE or ALKT or ISRG or SYK?
Over the past 5 years, Intuitive Surgical, Inc.
(ISRG) delivered a total return of +58. 7%, compared to -60. 2% for AudioEye, Inc. (AEYE). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus ALKT's -59. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — EDAP or AEYE or ALKT or ISRG or SYK?
By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.
55β versus AudioEye, Inc. 's 2. 29β — meaning AEYE is approximately 318% more volatile than SYK relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 143% for Edap Tms S. a. — giving it more financial flexibility in a downturn.
05Which is growing faster — EDAP or AEYE or ALKT or ISRG or SYK?
By revenue growth (latest reported year), Alkami Technology, Inc.
(ALKT) is pulling ahead at 32. 9% versus 10. 3% for Edap Tms S. a. (EDAP). On earnings-per-share growth, the picture is similar: AudioEye, Inc. grew EPS 30. 6% year-over-year, compared to -52. 9% for Edap Tms S. a.. Over a 3-year CAGR, ALKT leads at 29. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — EDAP or AEYE or ALKT or ISRG or SYK?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus -41. 5% for Edap Tms S. a. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -35. 6% for EDAP. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is EDAP or AEYE or ALKT or ISRG or SYK more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 32x versus Intuitive Surgical, Inc. 's 2. 01x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Stryker Corporation (SYK) trades at 19. 6x forward P/E versus 43. 8x for Intuitive Surgical, Inc. — 24. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EDAP: 44. 2% to $6. 00.
08Which pays a better dividend — EDAP or AEYE or ALKT or ISRG or SYK?
In this comparison, SYK (1.
1% yield) pays a dividend. EDAP, AEYE, ALKT, ISRG do not pay a meaningful dividend and should not be held primarily for income.
09Is EDAP or AEYE or ALKT or ISRG or SYK better for a retirement portfolio?
For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
55), 1. 1% yield, +187. 1% 10Y return). AudioEye, Inc. (AEYE) carries a higher beta of 2. 29 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +187. 1%, AEYE: +102. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between EDAP and AEYE and ALKT and ISRG and SYK?
These companies operate in different sectors (EDAP (Healthcare) and AEYE (Technology) and ALKT (Technology) and ISRG (Healthcare) and SYK (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: EDAP is a small-cap quality compounder stock; AEYE is a small-cap quality compounder stock; ALKT is a small-cap high-growth stock; ISRG is a mid-cap high-growth stock; SYK is a mid-cap quality compounder stock. SYK pays a dividend while EDAP, AEYE, ALKT, ISRG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.